https://bioprocessintl.com/bioprocess-insider/therapeutic-class/mesoblast-planning-capacity-hike-if-gvhd-candidate-is-effective-against-covid-19/
Confirmation from ItescuCOGS cuts
The manufacturing expansion will also help Mesoblast reduce its cost of goods sold (COGS) according to Itescu
“We will be moving to three dimensional bioreactors to reduce labor costs and improved manufacturing efficiencies. And these innovations will significantly reduce in the future our cost of goods.”
This was echoed by spokeswoman Julie Meldrum, who told us the 3D bioreactors “will be used to further optimize the manufacturing processes to increase yield and lower the cost of goods of our off-the-shelf cellular medicines.”
Mesoblast’s products are made through an agreement it has with Swiss CDMO Lonza. The deal grants exclusive access to Lonza’s cell therapy facilities in Singapore.
It also has an option for the construction of a facility by Lonza to meet Mesoblast’s long-term commercial objectives.
MSB Trading - 2020, page-12897
-
- There are more pages in this discussion • 10,264 more messages in this thread...
This thread is closed.
You may not reply to this discussion at this time.
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.17 |
Change
-0.025(2.10%) |
Mkt cap ! $1.330B | |||
| Open | High | Low | Value | Volume |
| $1.18 | $1.22 | $1.15 | $6.344M | 5.404M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 8683 | $1.16 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.17 | 32999 | 1 |
View Market Depth
| Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |